Dapsone as treatment adjunct in ARDS

References

• Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. doi:10.1038/s41572-019-0069-0.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374. doi:10.1007/s11427-020-1643-8.
   PubMed Web of Science ®Google Scholar
• Cardinal-Fernández P, Lorente JA, Ballén-Barragán A, Matute-Bello G. Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship. Annals ATS. 2017;14(6):844–850.
   Google Scholar
• Cardinal-Fernández P, Bajwa EK, Dominguez-Calvo A, Menéndez JM, Papazian L, Thompson BT. The presence of diffuse alveolar damage on open lung biopsy is associated with mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Chest. 2016;149(5):1155–1164. doi:10.1016/j.chest.2016.02.635.
   PubMed Web of Science ®Google Scholar
• Kao KC, Chang CH, Hung CY, Chiu LC, Huang CC, Hu HC. Survival predictor in patients with acute respiratory distress syndrome and diffuse alveolar damage undergoing open lung biopsy. PLoS One. 2017;12(7):e0180018. e0180018.
   PubMed Web of Science ®Google Scholar
• Kao KC, Hu HC, Chang CH, Hung CY, Chiu LC, et al. Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy. Crit Care. 2015;19(1):228. doi:10.1186/s13054-015-0949-y.
   PubMedGoogle Scholar
• Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med. 1996;154(1):76–81. doi:10.1164/ajrccm.154.1.8680703.
   PubMed Web of Science ®Google Scholar
• Chollet-Martin S, Montravers P, Gibert C, et al. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun. 1993;61(11):4553–4559.
   PubMed Web of Science ®Google Scholar
• Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(3):602–611.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Yokoi K, Mukaida N, et al. Pivotal role of interleukin-8 in the acute respiratory distress syndrome and cerebral reperfusion injury. J Leukoc Biol. 1997;62(5):581–587. doi:10.1002/jlb.62.5.581.
   PubMed Web of Science ®Google Scholar
• Buttignol M, Pires-Neto RC, Rossi E Silva RC, Albino MB, Dolhnikoff M, Mauad T. Airway and parenchyma immune cells in influenza A(H1N1)pdm09 viral and non-viral diffuse alveolar damage. Respir Res. 2017;18(1):147. doi:10.1186/s12931-017-0630-x.
   PubMedGoogle Scholar
• Sugamata R, Dobashi H, Nagao T, et al. Contribution of neutrophil-derived myeloperoxidase in the early phase of fulminant acute respiratory distress syndrome induced by influenza virus infection. Microbiol Immunol. 2012;56(3):171–182. doi:10.1111/j.1348-0421.2011.00424.x.
   PubMed Web of Science ®Google Scholar
• Mukaida N, Matsumoto T, Yokoi K, Harada A, Matsushima K. Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8). Inflamm Res. 1998;47(0):151–157.
   Google Scholar
• Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature. 1993;365(6447):654–657.
   PubMed Web of Science ®Google Scholar
• Yokoi K, Mukaida N, Harada A, Watanabe Y, Matsushima K. Prevention of endotoxemia-induced acute respiratory distress syndrome-like lung injury in rabbits by a monoclonal antibody to IL-8. Lab. Invest. 1997;76(3):375–384.
   PubMed Web of Science ®Google Scholar
• Bao Z, Ye Q, Gong W, Xiang Y, Wan H. Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury. Int Immunopharmacol. 2010;10(2):259–263.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Baker CS, Evans TW, Haslam PL. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J. 2000;15(5):895–901. doi:10.1034/j.1399-3003.2000.15e14.x.
   PubMed Web of Science ®Google Scholar
• Groeneveld AB, Raijmakers PG, Hack CE, Thijs LG. Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome. Cytokine. 1995;7(7):746–752. doi:10.1006/cyto.1995.0089.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Kunkel SL. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J. Investig. Med. 1994;42(4):640–651.
   PubMed Web of Science ®Google Scholar
• Miller EJ, Cohen AB, Nagao S, et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis. 1992;146(2):427–432. doi:10.1164/ajrccm/146.2.427.
   PubMed Web of Science ®Google Scholar
• Stapleton RD, Suratt BT, Neff MJ, et al. Bronchoalveolar fluid and plasma inflammatory biomarkers in contemporary ARDS patients. Biomarkers. 2019;24(4):352–359. doi:10.1080/1354750X.2019.1581840.
   PubMed Web of Science ®Google Scholar
• Nys M, Deby-Dupont G, Habraken Y, et al. Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kappaB in alveolar epithelial cell line: role of reactive oxygen/nitrogen species and cytokines. Nitric Oxide. 2003;9(1):33–43. doi:10.1016/j.niox.2003.07.001.
   PubMed Web of Science ®Google Scholar
• Williams AE, José RJ, Mercer PF, et al. Evidence for chemokine synergy during neutrophil migration in ARDS. Thorax. 2017;72(1):66–73.
   PubMed Web of Science ®Google Scholar
• Ikuta N, Taniguchi H, Kondoh Y, Takagi K, Hayakawa T. Sustained high levels of circulatory interleukin-8 are associated with a poor outcome in patients with adult respiratory distress syndrome. Intern Med. 1996;35(11):855–860.
   PubMed Web of Science ®Google Scholar
• Wozel VE. Innovative use of dapsone. Dermatol Clin. 2010;28(3):599–610. doi:10.1016/j.det.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–124. doi:10.1007/s00403-013-1409-7.
   PubMed Web of Science ®Google Scholar
• Karpel-Massler G, Kast RE, Siegelin MD, et al. Anti-glioma activity of dapsone and its enhancement by synthetic chemical modification. Neurochem Res. 2017;42(12):3382–3389. doi:10.1007/s11064-017-2378-6.
   PubMed Web of Science ®Google Scholar
• Bellon H, Vandermeulen E, Mathyssen C, et al. Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options. Transpl Int. 2017;30(4):388–397.
   PubMed Web of Science ®Google Scholar
• Boccellino M, Quagliuolo L, Alaia C, et al. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Curr Med Res Opin. 2016;32(11):1839–1848.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Cytokine and chemokine profile in amicrobial pustulosis of the folds: evidence for autoinflammation. Medicine (Baltimore). 2015;94(50):e2301. doi:10.1097/MD.0000000000002301.
   PubMed Web of Science ®Google Scholar
• Kast RE. Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness. Springerplus. 2015;4(1):638. doi:10.1186/s40064-015-1441-5.
   PubMedGoogle Scholar
• Lan CC, Wu CS, Huang SM, Wu IH, Chen GS. High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: new insights into impaired diabetic wound healing. Diabetes. 2013;62(7):2530–2538. doi:10.2337/db12-1714.E.
   PubMed Web of Science ®Google Scholar
• Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME. Why dapsone stops seizures and may stop neutrophils’ delivery of VEGF to glioblastoma. Br J Neurosurg. 2012;26(6):813–817. doi:10.3109/02688697.2012.674577.
   PubMed Web of Science ®Google Scholar
• Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME. The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anticancer Agents Med Chem. 2011;11(8):756–761. doi:10.2174/187152011797378805.
   PubMed Web of Science ®Google Scholar
• Kanoh S, Tanabe T, Rubin BK. Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret. Chest. 2011;140(4):980–990.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Reimer S, Kruse N, Bröcker EB, Zillikens D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2001;124(1):157–162.
   PubMed Web of Science ®Google Scholar
• Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992;98(2):135–140.
   PubMed Web of Science ®Google Scholar
• Bangsgaard N, Houtkamp M, Schuurhuis DH, et al. Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS One. 2012;7(6):e39706. doi:10.1371/journal.pone.0039706.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. doi:10.1007/s00281-017-0629-x.
   PubMed Web of Science ®Google Scholar
• Molinelli E, Paolinelli M, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019;15(5):367–379.
   PubMed Web of Science ®Google Scholar
• Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: an entity bridging monogenic and polygenic autoinflammatory disorders, and beyond. J Eur Acad Dermatol Venereol. 2020;34(4):685–690. doi:10.1111/jdv.15984.
   Web of Science ®Google Scholar
• Roman C, Dima B, Muyshont L, Schurmans T, Gilliaux O. Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature. Eur J Pediatr. 2019;178(8):1275–1281.
   PubMed Web of Science ®Google Scholar
• Ghaoui N, Hanna E, Abbas O, Kibbi AG, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020. [Epub ahead of print] doi:10.1111/ijd.14761.
   PubMed Web of Science ®Google Scholar
• Martin WJ, 2nd, Kachel DL. Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Am Rev Respir Dis. 1985;131(4):544–547. doi:10.1164/arrd.1985.131.4.544.
   PubMedGoogle Scholar
• Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129(5):507–513. doi:10.1111/j.1365-2133.1993.tb00476.x.
   PubMed Web of Science ®Google Scholar
• Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol. 1990;30(5):761–767. doi:10.1111/j.1365-2125.1990.tb03847.x.
   PubMed Web of Science ®Google Scholar
• Coleman MD, Rhodes LE, Scott AK, et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol. 1992;34(3):244–249.,. doi:10.1111/j.1365-2125.1992.tb04131.x.
   PubMed Web of Science ®Google Scholar
• Goolamali SI, Macfarlane CS. The use of cimetidine to reduce dapsone-dependent haematological side-effects in a patient with mucous membrane pemphigoid. Clin Exp Dermatol. 2009;34(8):e1025–6. doi:10.1111/j.1365-2230.2009.03710.x.
   PubMed Web of Science ®Google Scholar
• Rhodes LE, Tingle MD, Park BK, et al. Cimetidine improves the therapeutic ⁄ toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol. 2006;132(2):257–262. doi:10.1111/j.1365-2133.1995.tb05022.x.
   Google Scholar
• Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: a primer for clinicians. Ann Pharmacother. 2011;45(9):1103–1115. doi:10.1345/aph.1Q139.
   PubMed Web of Science ®Google Scholar
• Kinehara Y, Kijima T, Inoue K, et al. Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluid. Intern Med. 2015;54(7):827–831. doi:10.2169/internalmedicine.54.3406.
   PubMed Web of Science ®Google Scholar